S1 Dataset -
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://figshare.com/articles/dataset/S1_Dataset_-/24842869
下载链接
链接失效反馈官方服务：
资源简介：
Background
Ablation or surgical excision is the typical treatment of anal high-grade squamous intraepithelial lesions (HSIL). Recurrences are common due to the persistence of underlying human papillomavirus (HPV) infection. Additional well-tolerated and effective non-surgical options for HPV-associated anal disease are needed.
Methods
This 3+3 dose escalation Phase I clinical trial evaluated the safety and tolerability of artesunate suppositories in the treatment of patients with biopsy-proven HSIL.
Results
The maximal tolerated dose was 400 mg, administered in 3 cycles. All adverse events associated with the use 200- and 400-mg artesunate suppositories were Grade 1. At the 600-mg dose, patients experienced clinically significant nausea.
Conclusion
Artesunate suppositories are a safe treatment option for anal HSIL.
创建时间：
2023-12-15
